Abstract 1251P
Background
Abnormal methylation of cell-free DNA (cfDNA) enables the diagnosis of lung cancer. In this study, we aimed to identify the best methylation marker for distinguishing lung cancer from healthy individuals, and then develop a deep learning algorithm using methylation and fragment size profiles (MFS) of cfDNA in that region.
Methods
We obtained 828 tissue samples from lung cancer patients, 74 adjacent normal tissue samples, and 656 samples of normal whole blood from the TCGA database and generated genome-wide tissue and plasma methylome data from healthy individuals and lung cancer patients using 215 Methylated DNA immunoprecipitation sequencing (MeDIP-Seq) and 24 Enzymatic Methyl-seq (EM-seq). A total of 366 DNA methylation markers were selected based on the methylation profiling of these datasets, and a targeted EM-seq panel was designed on these markers. The panel was used to produce 142 lung cancer samples (stage I: 26%, II: 11%, III: 42%, IV: 11%, unknown: 11%) and 56 healthy samples. MFS was trained on hyper- and hypo-methylated regions using convolutional neural networks. To confirm the limit of detection (LOD), sequencing was performed on diluted samples of healthy and lung cancer cfDNA with different ratios (tumor fractions of 0.1%, 0.5%, and 1%).
Results
We found that the performance was better in hypo-methylated regions than in hyper-methylated regions. The lung cancer detection performance in the test and external sets reached an accuracy of 81.5% (CI: 78.2% to 87.0%) and an AUC of 0.87 (CI: 0.83 to 0.94). At a specificity of 80%, the sensitivity for cancer detection was 77.5% (CI: 67.3% to 99.4%). The sensitivity for Lung Adenocarcinoma and Lung Squamous Cell Carcinoma at 80% specificity was 61.1% (CI: 42.7% to 94.4%) and 85.7% (CI: 71.4% to 100.0%), respectively. With serial dilution results, we detected down to 0.1% tumor fraction with a specificity of 80%.
Conclusions
This study developed and validated a methylation marker and deep learning model that can distinguish between lung cancer patients and healthy individuals using methylation and size information. This approach provides a sensitive and accurate diagnostic tool for lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
GC Genome.
Funding
Ministry of Health and Welfare.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1219P - Artificial intelligence-based breast cancer detection facilitates automated prognosis marker assessment using multiplex fluorescence immunohistochemistry
Presenter: Tim Mandelkow
Session: Poster session 14
1220P - Comprehensive diagnose of programmed death-ligand 1 from two-dimensional to three-dimensional in breast cancer with computer-aided artificial intelligence system
Presenter: Yi-Hsuan Lee
Session: Poster session 14
1221P - The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors
Presenter: Lorena Incorvaia
Session: Poster session 14
1222P - Detection of androgen-receptor splice variant 7 messenger RNA in circulating tumor cells of prostate cancer by in vitro assay
Presenter: Hoin Kang
Session: Poster session 14
1223P - Homologous recombination deficiency (HRD) testing on ovarian cancer ascites: A feasibility study
Presenter: Alberto Ranghiero
Session: Poster session 14
1224P - Detection of circulating tumor DNA (ctDNA) in untreated patients (pts) with cancer: Implications for early cancer detection (ECD)
Presenter: Yoshiaki Nakamura
Session: Poster session 14
1225P - Combining ctDNA and tissue-based-genomic profiling in advanced cancer: A real-world evidence prospective study in non-Western patients treated at Gustave Roussy cancer campus
Presenter: Tony Ibrahim
Session: Poster session 14
1226P - Multi-site validation of a deep learning solution for HER2 profiling of breast cancer from H&E-stained pathology slides
Presenter: Salim Arslan
Session: Poster session 14
1227P - Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer
Presenter: Magdalena Staniszewska
Session: Poster session 14
1228P - A circulating tumor cell (CTC) based assay for diagnostic immunocytochemistry profiling of lung cancer
Presenter: Nitesh Rohatgi
Session: Poster session 14